The comparison of Filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: A single center experience from Turkey

Sivgin S., Karakus E., KAYNAR L., Kurnaz F., Pala C., Keklik M., ...More

TRANSFUSION AND APHERESIS SCIENCE, vol.48, no.3, pp.315-320, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1016/j.transci.2013.04.007
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.315-320
  • Keywords: Autologous hematopoietic stem cell transplantation, Stem cell mobilization, G-CSF, Biosimilars, COLONY-STIMULATING FACTOR, NON-HODGKINS-LYMPHOMA, FEBRILE NEUTROPENIA, G-CSF, MULTIPLE-MYELOMA, LUNG-CANCER, BREAST-CANCER, CHEMOTHERAPY, XM02, DURATION
  • Erciyes University Affiliated: Yes


Objectives and aim: Patients affected by hematological malignancies can often benefit from high dose chemotherapy followed by peripheral blood stem cells (PBSCs) transplantation. Different strategies have been used to mobilize an adequate number of PBSC, including granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy plus G-CSF. In this study, we aimed to compare the efficacy profile of different G-CSF agents including filgrastim (Neupogen (R)), biosimilar filgrastim (Leucostim (R)) and Lenograstim (Granocyte (R)) on CD34(+) mobilization in patients who underwent autologous hematopoietic stem cell transplantation (autoHSCT).